[Cutaneous events during anti-TNF alpha therapy: a prospective observational study of 41 cases].
BACKGROUND
The cutaneous adverse effects of TNFalpha inhibitors and their potential implication in the onset of associated dermatoses remain poorly understood.


OBJECTIVE
To describe the different clinical dermatological situations seen in patients treated with TNFalpha inhibitors.


METHODS
We conducted a prospective, observational study of patients followed at the Dermatology Department of the CHU Nord university teaching hospital of Marseilles. All patients, referred by various departments, were treated with TNFalpha inhibitors and presented cutaneous events.


RESULTS
Forty-one patients were included in the study. Various cutaneous manifestations were observed, including: 15 psoriatic rashes, six skin infections, three eczema rashes, three cases of lupic syndrome, two anaphylactic reactions to infusion and two cutaneous drug reactions. An original case of parapsoriasis was observed. Cutaneous tumors are rarely described.


CONCLUSIONS
This study confirms the multiple clinical dermatological situations observed in patients treated with TNFalpha inhibitors and illustrates the need for good coordination between dermatologists and other specialists in order to ensure optimal management of this population.
Bonnet
N
N
Service de dermatologie, CHU Nord, Assistance publique-Hôpitaux de Marseille, université de la Méditerranée, chemin des Bourrely, 13915 Marseille cedex 20, France. nathalie.bonnet@ap-hm.fr
Guis
S
S
Koeppel
M-C
MC
Roudier
J
J
Grimaud
J-C
JC
Jean-Pastor
M-J
MJ
Berbis
P
P
D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000707:Anaphylaxis / Q000139:chemically induced; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003875:Drug Eruptions / Q000453:epidemiology / Q000209:etiology*; D004485:Eczema / Q000139:chemically induced; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012874:Skin Diseases, Infectious / Q000209:etiology; D017444:Skin Diseases, Papulosquamous / Q000139:chemically induced; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept